A new treatment for chronic wound healing using a fibronectin mimetic
Fibronectin matrix mimetic, Chimectin as a first-in-class therapeutic for chronic wound healing
['FUNDING_SBIR_1'] · EDI THERAPEUTICS LLC · NIH-10917587
This study is testing a new treatment called Chimectin to help heal stubborn wounds faster, especially for people with diabetes, by encouraging the body to repair itself better.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EDI THERAPEUTICS LLC (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-10917587 on ClinicalTrials.gov |
What this research studies
This research investigates a novel therapeutic approach for chronic wounds by utilizing a fibronectin matrix mimetic called Chimectin. The therapy aims to enhance tissue regeneration by promoting cell adhesion, migration, and local blood vessel formation. By applying this treatment topically to wounds, the researchers hope to accelerate healing processes that are often impaired in patients with chronic wounds, particularly those with diabetes. The study will involve preclinical testing to evaluate the effectiveness of Chimectin in improving wound healing outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with chronic wounds, especially those related to diabetes or other conditions that impair healing.
Not a fit: Patients with acute wounds or those whose healing is not compromised by underlying conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients suffering from chronic wounds, potentially reducing complications and healthcare costs.
How similar studies have performed: Previous research has shown promise in using fibronectin-based therapies for wound healing, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
ROCHESTER, UNITED STATES
- EDI THERAPEUTICS LLC — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GRAHAM, MARTIN — EDI THERAPEUTICS LLC
- Study coordinator: GRAHAM, MARTIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer